Cervical Cancer

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer.

The FDA has set a Prescription Drug User Fee Act date of May 9, 2024 for the potential full approval of tisotumab vedotin for those with recurrent or metastatic cervical cancer.

Investigators note a trend towards improved overall survival with cadonilimab plus chemotherapy with or without bevacizumab among those with cervical cancer in the phase 3 AK104-303 trial.

Findings from the phase 2 SKYSCRAPER-04 trial support dual targeting of TIGIT and PD-L1 in patients with PD-L1–positive cervical cancer, says Ritu Salani, MD.

Results from the phase 3 GCIG INTERLACE trial highlight progression-free survival and overall survival improvements with induction chemotherapy plus chemoradiotherapy for patients with locally advanced cervical cancer.

Radical hysterectomies result in worse symptom experience, body image, menopausal symptoms, sexual worry, sex activity and enjoyment compared with simple hysterectomy in those with early-stage cervical cancer.

Progression-free survival benefit appears consistent in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin.

Combining atezolizumab with bevacizumab and chemotherapy may be a new frontline therapy option for patients with metastatic, persistent or recurrent cervical cancer, says Ana Oaknin, MD, PhD.

Data from the phase 3 KEYNOTE-A18 study may support pembrolizumab plus chemoradiotherapy as a new standard of care for those with newly diagnosed, high-risk, locally advanced cervical cancer.

Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.

Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.

Pembrolizumab combination yielded an improved progression-free survival benefit vs placebo in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Findings from the phase 3 KEYNOTE-A18 trial support the supplemental biologics license application for a pembrolizumab-based regimen as a treatment for patients with newly diagnosed, high-risk, locally advanced cervical cancer.

Investigators report acceptable morbidity and health-related quality of life with neoadjuvant chemotherapy plus surgery and concomitant chemoradiotherapy in those with cervical cancer.

The safety profile of tisotumab vedotin-tftv among those with recurrent or metastatic cervical cancer in the phase 3 innovaTV 301 trial appears to be comparable with prior reports of the agent.

The safety profile of pembrolizumab among patients with high-risk locally advanced cervical cancer in the phase 3 KEYNOTE-A18 trial appears to be consistent with previous reports of the agent.

Simple hysterectomy may become the new standard of care for patients with low-risk, early-stage cervical cancer, according to an expert from Université Laval in Quebec City, Canada.

Pembrolizumab plus chemotherapy with or without bevacizumab yields a survival benefit in PD-L1 positive patients with cervical cancer in the phase 3 KEYNOTE-826 trial.

Findings from the phase 3 OUTBACK trial show that following standard cisplatin-based chemotherapy with adjuvant chemotherapy resulted in increased toxicity among patients with cervical cancer.

Adding pembrolizumab to chemotherapy with or without bevacizumab can help patients with persistent, recurrent, or metastatic cervical cancer “live longer and better,” according to an expert from the University of Arizona College of Medicine.

A novel smoking cessation treatment for survivors of cervical cancer or cervical intraepithelial neoplasia appears to improve rates of abstinence in the short-term, but approximately matches the efficacy of standard treatment at 18 months.

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.

According to phase 1b/2 HPV001 study data, VTP-200 appears to produce no serious adverse effects in patients with low-grade cervical human papillomavirus lesions.

The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.

The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.

Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.

ATG-008 combined with toripalimab produced an objective response rate of 52.4% among patients with relapsed or metastatic cervical cancer in the phase 1/2 TORCH-2 study.

Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.